Final progression-free survival analysis of BOLERO-2: a phase Ill trial of everolimus for postmenopausal women with advanced breast cancer

被引：3
|
作者：
Piccart, M.
Baselga, J.
Noguchi, S.
Burris, H.
Gnant, M.
Hortobagyi, G.
Mukhopadhyay, P.
Taran, T.
Sahmoud, T.
Rugo, H.
机构：
[1] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Osaka Univ, Osaka, Japan
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-126-04-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-04-02
引用
收藏
页数：2
相关论文
共 50 条
  • [21] ESTIMATION OF THE QUALITY ADJUSTED PROGRESSION FREE SURVIVAL OF THE TREATMENT ARMS OF THE BOLERO-2 TRIAL
    Ali, A. A.
    Adunlin, G.
    Tawk, R.
    Diaby, V
    VALUE IN HEALTH, 2014, 17 (03) : A89 - A89
  • [22] Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2
    Hortobagyi, Gabriel N.
    NEOPLASIA, 2015, 17 (03): : 279 - 288
  • [23] BOLERO-2: EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS PLUS EXEMESTANE IN ADVANCED BREAST CANCER
    Campone, M.
    Gnant, M.
    Neven, P.
    Pistilli, B.
    Rugo, H. S.
    Baselga, J.
    Bauly, H.
    Taran, T.
    Sahmoud, T.
    Hortobagyi, G.
    BREAST, 2013, 22 : S111 - S111
  • [24] Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
    Rugo, H. S.
    Pritchard, K. I.
    Gnant, M.
    Noguchi, S.
    Piccart, M.
    Hortobagyi, G.
    Baselga, J.
    Perez, A.
    Geberth, M.
    Csoszi, T.
    Chouinard, E.
    Srimuninnimit, V.
    Puttawibul, P.
    Eakle, J.
    Feng, W.
    Bauly, H.
    El-Hashimy, M.
    Taran, T.
    Burris, H. A., III
    ANNALS OF ONCOLOGY, 2014, 25 (04) : 808 - 815
  • [25] Comparative efficacy of everolimus in combination with exemestane and chemotherapy for advanced breast cancer in terms of progression-free survival
    Cope, S.
    Zhang, J.
    Smiechowski, B.
    Gurunath, S.
    Saletan, S.
    Jansen, J. P.
    Schmid, P.
    CANCER RESEARCH, 2013, 73
  • [26] Immunosuppresant everolimus improves progression-free survival in advanced kidney cancer patients
    不详
    ONCOLOGY-NEW YORK, 2008, 22 (07): : 841 - 841
  • [27] Progression-free survival as a surrogate endpoint in advanced breast cancer
    Miksad, Rebecca A.
    Zietemann, Vera
    Gothe, Raffaella
    Schwarzer, Ruth
    Conrads-Frank, Annette
    Schnell-Inderst, Petra
    Stollenwerk, Bjoern
    Siebert, Uwe
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2008, 24 (04) : 371 - 383
  • [28] ELACESTRANT PROLONGS PROGRESSION-FREE SURVIVAL IN ADVANCED BREAST CANCER
    不详
    CANCER DISCOVERY, 2022, 12 (07) : 1609 - 1609
  • [29] BOLERO-2: Efficacy and safety of first-line everolimus plus exemestane in advanced breast cancer.
    Rugo, Hope S.
    Campone, Mario
    Gnant, Michael
    Neven, Patrick
    Pistilli, Barbara
    Baselga, Jose
    Bauly, Hounayda
    Taran, Tanya
    Sahmoud, Tarek
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [30] Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial
    Diaby, Vakaramoko
    Adunlin, Georges
    Ali, Askal Ayalew
    Tawk, Rima
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (03) : 669 - 673
12345